Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 51, 2016 - Issue 9
Submit an article Journal homepage
2,908
Views
47
CrossRef citations to date
0
Altmetric
Original Article

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis

Radan KeilDepartment of Internal Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic; Correspondence[email protected]
,
Martin WasserbauerDepartment of Internal Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic;
,
Zdena Zádorová2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University in Prague, FNKV, Prague, Czech Republic;
,
Jan Hajer2nd Department of Internal Medicine, 3rd Faculty of Medicine, Charles University in Prague, FNKV, Prague, Czech Republic;
,
Pavel DrastichDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;
,
Pavel WohlDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;
,
Marek BenešDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;
,
Martina BojkováClinic of Internal Medicine, University Hospital Ostrava, Ostrava, Czech Republic;
,
Pavel SvobodaClinic of Internal Medicine, University Hospital Ostrava, Ostrava, Czech Republic;
,
Michal Konečný2nd Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic;
,
Přemysl FaltDigestive Diseases Center, Vítkovice Hospital, Ostrava, Czech Republic;
,
Tomáš Vaňásek2nd Department of Internal Medicine-Gastroenterology, University Hospital Hradec Králové, Hradec Králové, Czech Republic;
,
Martin PeštaDepartment of Internal Medicine, Hospital Na Bulovce, Prague, Czech Republic;
,
František Pešek2nd Department of Internal Medicine, University Hospital Plzeň-Bory, Plzeň, Czech Republic;
,
Luděk Bouchner2nd Department of Internal Medicine, University Hospital Plzeň-Bory, Plzeň, Czech Republic;
,
Jana Koželuhová4th Department of Internal Medicine – Clinic of Gastroenterology and Hepatology, The General University Hospital in Prague, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic;
,
Aleš Novotný4th Department of Internal Medicine – Clinic of Gastroenterology and Hepatology, The General University Hospital in Prague, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic;
,
Lucie BartůskováDepartment of Economic and Social Policy, University of Economics, Prague, Czech Republic
&
Julius ŠpičákDepartment of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic;
show all
Pages 1062-1068 | Received 13 Dec 2015, Accepted 31 Jan 2016, Published online: 22 Mar 2016

Citations (47)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, Maria Giovanna Graziani, Roberto Lorenzetti, Francesco Luzza, Pietro Paese, Antonio Penna, Roberta Pica, Giuseppe Pranzo, Stefano Rodinò, Antonella Scarcelli, Costantino Zampaletta, Lorenzo Brozzi, Clelia Cicerone, Andrea Cocco, Gianluigi De’ Angelis, Laura Donnarumma, Serafina Fiorella, Chiara Iannelli, Tiziana Larussa, Marco Le Grazie, Ileana Luppino, Costantino Meucci, Roberto FaggianI, Cristiano Pagnini, Patrizia Perazzo, Kryssia Isabel Rodriguez-Castro, Rodolfo Sacco, Ladislava Sebkova, Mariaelena Serio, Alberta De Monti, Marcello Picchio, Daniele Napolitano, Elisa Schiavoni, Laura Turchini, Franco Scaldaferri, Daniela Pugliese, Luisa Guidi, Lucrezia Laterza, Giuseppe Privitera, Marco Pizzoferrato, Loris R. Lopetuso, Alessandro Armuzzi, Walter Elisei, Giovanni Maconi & Alfredo Papa. (2022) Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opinion on Biological Therapy 22:2, pages 313-320.
Read now
Ahmad Albshesh & Shomron Ben-Horin. (2019) CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 19:10, pages 971-978.
Read now
Andras Tarnok, Zoltan Kiss, Orsolya Kadenczki & Gabor Veres. (2019) Characteristics of biological therapy in pediatric patients with Crohn’s disease. Expert Opinion on Biological Therapy 19:3, pages 181-196.
Read now
Raguprakash Ratnakumaran, Natalie To, David J. Gracie, Christian P. Selinger, Anthony O'Connor, Tanya Clark, Nicola Carey, Katherine Leigh, Lynsey Bourner, Alexander C. Ford & P. John Hamlin. (2018) Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology 53:6, pages 700-707.
Read now
Tommaso Gabbani, Simona Deiana & Vito Annese. (2017) CT-P13: design, development, and place in therapy. Drug Design, Development and Therapy 11, pages 1653-1661.
Read now
Klaudia Farkas, Mariann Rutka, Tamás Ferenci, Ferenc Nagy, Anita Bálint, Renáta Bor, Ágnes Milassin, Anna Fábián, Kata Szántó, Zsuzsanna Végh, Zsuzsanna Kürti, Péter L. Lakatos, Zoltán Szepes & Tamás Molnár. (2017) Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opinion on Biological Therapy 17:11, pages 1325-1332.
Read now
J. Braun & J. Kay. (2017) The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety 16:3, pages 289-302.
Read now

Articles from other publishers (40)

Xiaochun Yang, Deyong Zeng, Chongyang Li, Wenchen Yu, Guilin Xie, Yingchun Zhang & Weihong Lu. (2023) Therapeutic potential and mechanism of functional oligosaccharides in inflammatory bowel disease: a review. Food Science and Human Wellness 12:6, pages 2135-2150.
Crossref
Martin Wasserbauer, Stepan Hlava, Jiri Drabek, Jan Stovicek, Petra Minarikova, Lenka Nedbalova, Tomas Drasar, Zdena Zadorova, Jiri Dolina, Stefan Konecny, Vladimír Kojecky, Jana Kozeluhova, Pavlina Cernikova, Dita Pichlerova, Barbora Kucerova, Stepan Coufal & Radan Keil. (2022) Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring. PLOS ONE 17:8, pages e0271299.
Crossref
Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós & Jose María Paredes. (2021) Real-world data on the infliximab biosimilar CT-P13 (Remsima ® ) in inflammatory bowel disease . World Journal of Clinical Cases 9:36, pages 11285-11299.
Crossref
Richard H. ParrishIIII. (2021) Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary. Gastroenterology Insights 12:3, pages 293-301.
Crossref
Seung Wook Hong, Yong-Gil Kim & Byong Duk Ye. (2020) An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases. Immunotherapy 12:9, pages 609-623.
Crossref
Helena Martínez-Lozano, José Miranda-Bautista, Yago González-Lama, Daniel Carpio, Manuel Barreiro-de Acosta, José L. Pérez-Calle, Lucía Relea Pérez, Keyla Villa, Virginia Matallana, Marta Calvo, María I. Vera, Pablo Pérez Galindo, Natalia Mora-Cuadrado, Pilar Lopez-Serrano, Ignacio Marín-Jiménez & Luis Menchén. (2020) Comparison of original and biosimilar infliximab (CTP-13) in biologic-na�ve patients with Crohn�s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain.. Revista Española de Enfermedades Digestivas.
Crossref
Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki Yamaguchi, Tomohito Wakabayashi, Mayako Uchida & Kazunori Iwanaga. (2019) Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database. Journal of Pharmaceutical Health Care and Sciences 5:1.
Crossref
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe & Toshifumi Hibi. (2019) Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intestinal Research 17:4, pages 504-515.
Crossref
Mahmoud Ahmed Ebada, Abdelmagid M. Elmatboly, Ahmed Said Ali, Ahmed Mohamed Ibrahim, Notila Fayed, Ahmed Faisal Faisal & Souad Alkanj. (2019) An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. International Journal of Colorectal Disease 34:10, pages 1633-1652.
Crossref
Nam Hee Kim, Ji Hyun Lee, Sung Noh Hong, Hyuk Yoon, Hyoun Woo Kang, Suck‐Ho Lee, Jong Pil Im, Jae Myung Cha, Chang Soo Eun, Ji Won Kim, Chang Hwan Choi & Dong Il Park. (2019) Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. Journal of Gastroenterology and Hepatology 34:9, pages 1523-1532.
Crossref
Jian Shen, Jiazheng Cheng, Shengguo Zhu, Jun Zhao, Qingyan Ye, Yinyin Xu, Huilin Dong & Xianhui Zheng. (2019) Regulating effect of baicalin on IKK/IKB/NF-kB signaling pathway and apoptosis-related proteins in rats with ulcerative colitis. International Immunopharmacology 73, pages 193-200.
Crossref
Remo Panaccione, A. Hillary Steinhart, Brian Bressler, Reena Khanna, John K. Marshall, Laura Targownik, Waqqas Afif, Alain Bitton, Mark Borgaonkar, Usha Chauhan, Brendan Halloran, Jennifer Jones, Erin Kennedy, Grigorios I. Leontiadis, Edward V. LoftusJr.Jr., Jonathan Meddings, Paul Moayyedi, Sanjay Murthy, Sophie Plamondon, Greg Rosenfeld, David Schwartz, Cynthia H. Seow, Chadwick Williams & Charles N. Bernstein. (2019) Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Clinical Gastroenterology and Hepatology 17:9, pages 1680-1713.
Crossref
Remo Panaccione, A Hillary Steinhart, Brian Bressler, Reena Khanna, John K Marshall, Laura Targownik, Waqqas Afif, Alain Bitton, Mark Borgaonkar, Usha Chauhan, Brendan Halloran, Jennifer Jones, Erin Kennedy, Grigorios I Leontiadis, Edward V LoftusJrJr, Jonathan Meddings, Paul Moayyedi, Sanjay Murthy, Sophie Plamondon, Greg Rosenfeld, David Schwartz, Cynthia H Seow, Chadwick Williams & Charles N Bernstein. (2019) Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease. Journal of the Canadian Association of Gastroenterology 2:3, pages e1-e34.
Crossref
Silvio Danese & Gionata Fiorino. (2019) Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Current Medicinal Chemistry 26:2, pages 280-287.
Crossref
Laura Martelli & Laurent Peyrin-Biroulet. (2019) Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review. Current Medicinal Chemistry 26:2, pages 270-279.
Crossref
Soo-Kyung ParkWon MoonEun Soo KimSang Hyun ParkDong Il Park. (2019) Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians. The Korean Journal of Gastroenterology 74:6, pages 333.
Crossref
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas & Federico Argüelles-Arias. (2019) Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therapeutic Advances in Gastroenterology 12, pages 175628481985805.
Crossref
Ágnes Milassin, Anna Fábián & Tamás Molnár. (2019) Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therapeutic Advances in Gastroenterology 12, pages 175628481984274.
Crossref
Lissy de Ridder, Amit Assa, Jiri Bronsky, Claudio Romano, Richard K. Russell, Nadeem A. Afzal, Almuthe C. Hauer, Daniela Knafelz, Paolo Lionetti, Caterina Strisciuglio, Gábor Veres, Harland Winter, Victorien M. Wolters, Malgorzata Sladek, Arnold G. Vulto & Jorge A. Dias. (2019) Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. Journal of Pediatric Gastroenterology & Nutrition 68:1, pages 144-153.
Crossref
Soo-Kyung Park, Tadakazu Hisamatsu, Zhihua Ran, Shu-Chen Wei & Dong Il Park. (2018) Knowledge and viewpoints on biosimilar monoclonal antibodies from members of the Asian Organization of Crohn’s and Colitis: comparison with European Crohn’s and Colitis members. Intestinal Research.
Crossref
Neil Chanchlani, Kajal Mortier, Linda J. Williams, Rafeeq Muhammed, Marcus K.H. Auth, Mike Cosgrove, Andrew Fagbemi, John Fell, Sonny Chong, Veena Zamvar, Warren Hyer, W. Michael Bisset, Mary-Anne Morris, Astor Rodrigues, Sally G. Mitton, Su Bunn, R. Mark Beattie, Anne Willmott, David C. Wilson & Richard K. Russell. (2018) Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort. Journal of Pediatric Gastroenterology & Nutrition 67:4, pages 513-519.
Crossref
Frank I. Scott & Gary R. Lichtenstein. (2018) Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Current Treatment Options in Gastroenterology 16:1, pages 147-164.
Crossref
Klaudia Farkas & Tamás Molnár. (2018) A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease. Immunotherapy 10:2, pages 107-117.
Crossref
Akos Ilias, Lorant Gonczi, Zuszsanna Kurti & Peter L. Lakatos. (2018) Biosimilars in ulcerative colitis: When and for who?. Best Practice & Research Clinical Gastroenterology 32-33, pages 35-42.
Crossref
Rahul Maheshwari, Piyoosh Sharma, Ankit Seth, Neha Taneja, Muktika Tekade & Rakesh K. Tekade. 2018. Dosage Form Design Considerations. Dosage Form Design Considerations 337 369 .
Muhammad Ilham Abdul Hafidz, Thevaraajan Jayaraman, Raja Affendi Raja Ali & Yeong Yeh Lee. (2017) Are We Ready for Biosimilars in Gastroenterology?. EMJ Gastroenterology, pages 83-89.
Crossref
Dae Hyun Yoo. (2017) Comparative effectiveness of the biosimilar CT-P13. Journal of Comparative Effectiveness Research 6:8, pages 693-712.
Crossref
Cristina Scavone, Liberata Sportiello, Liberato Berrino, Francesco Rossi & Annalisa Capuano. (2017) Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve. Pharmacological Research 119, pages 265-271.
Crossref
F. Argüelles-Arias, M. F. Guerra Veloz, R. Perea Amarillo, A. Vilches-Arenas, L. Castro Laria, B. Maldonado Pérez, D. Chaaro, A. Benítez Roldán, V. Merino, G. Ramírez, A. Caunedo Álvarez & M. Romero Gómez. (2017) Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. Digestive Diseases and Sciences 62:5, pages 1305-1312.
Crossref
Y. Komaki, A. Yamada, F. Komaki, D. Micic, A. Ido & A. Sakuraba. (2017) Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 45:8, pages 1043-1057.
Crossref
Shannon Chang & Stephen Hanauer. (2017) Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology 15:1, pages 53-70.
Crossref
Gionata Fiorino, Natalia Manetti, Alessandro Armuzzi, Ambrogio Orlando, Angela Variola, Stefanos Bonovas, Fabrizio Bossa, Giovanni Maconi, Renata DʼIncà, Paolo Lionetti, Laura Cantoro, Walter Fries, Maria L. Annunziata, Francesco Costa, Maria M. Terpin, Livia Biancone, Claudio C. Cortelezzi, Arnaldo Amato, Sandro Ardizzone, Silvio Danese, Luisa Guidi, Giulia Rizzuto, Arianna Massella, Angelo Andriulli, Alessandro Massari, Greta Lorenzon, Silvia Ghione, Anna Kohn, Agostino Ventra & Vito Annese. (2017) The PROSIT-BIO Cohort. Inflammatory Bowel Diseases 23:2, pages 233-243.
Crossref
Massimo Radin, Savino Sciascia, Dario Roccatello & Maria Jose Cuadrado. (2016) Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs 31:1, pages 37-49.
Crossref
Violeta Razanskaite, Marion Bettey, Louise Downey, Julia Wright, James Callaghan, Miles Rush, Simon Whiteoak, Sarah Ker, Kim Perry, Caron Underhill, Eren Efrem, Iftikar Ahmed & Fraser Cummings. (2017) Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. Journal of Crohn's and Colitis, pages jjw216.
Crossref
Baohai Liu, Xuehua Piao, Lianyi Guo, Guijun Wang, Weihua Sun, Leming Gao, Xuefeng Zheng & Yanli Fang. (2017) A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis. Evidence-Based Complementary and Alternative Medicine 2017, pages 1-8.
Crossref
Silvio Danese, Gionata Fiorino, Tim Raine, Marc Ferrante, Karen Kemp, Jaroslaw Kierkus, Peter L. Lakatos, Gerassimos Mantzaris, Janneke van der Woude, Julian Panes & Laurent Peyrin-Biroulet. (2017) ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update. Journal of Crohn's and Colitis 11:1, pages 26-34.
Crossref
Silvio Danese, Stefanos Bonovas & Laurent Peyrin-Biroulet. (2016) Biosimilars in IBD: from theory to practice. Nature Reviews Gastroenterology & Hepatology 14:1, pages 22-31.
Crossref
Sudarshan Paramsothy, David T. Rubin & Remo Panaccione. 2017. Inflammatory Bowel Disease. Inflammatory Bowel Disease 217 232 .
Shomron Ben-Horin, Niels Vande Casteele, Stefan Schreiber & Peter Laszlo Lakatos. (2016) Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation. Clinical Gastroenterology and Hepatology 14:12, pages 1685-1696.
Crossref
Lydia C. T. Buer, Bjørn A. Moum, Milada Cvancarova, David J. Warren, Asle W. Medhus & Marte Lie Høivik. (2016) Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. Journal of Crohn's and Colitis, pages jjw166.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.